Cardiovasc Res:生物疗法有希望用于动脉粥样硬化的治疗。

2019-02-24 Secret 巴典医学

最新研究发现,生物疗法可显着改善严重银屑病患者的冠状动脉斑块情况。

最新研究发现,生物疗法可显着改善严重银屑病患者的冠状动脉斑块情况。

马里兰州贝塞斯达国家心脏、肺和血液研究所的Nehal N.Mehta博士说:“生物疗法的抗炎作有希望用于动脉粥样硬化的治疗,但仍需要进行更深入的研究。”

严重的银屑病引起早期心肌梗死和冠状动脉疾病风险升高的发生率类似于2型糖尿病。生物疗法是否会改变冠状动脉的特性尚不清楚。

Mehta博士及其同事对121名参与了正在进行的银屑病、动脉粥样硬化和心脏代谢疾病倡议的中重度银屑病患者进行了生物治疗,并对其进行生物治疗前后冠状动脉斑块的特征进行了分析。

他们根据银屑病面积和严重程度指数(PASI)对这些患者评分,结果显示,非钙化斑块负荷与传统血管危险因素和皮肤病严重程度显着相关。

在一年的随访中,89名生物治疗患者的Pasi评分和高敏C反应蛋白(hsCRP)水平有了显着提高,而32名非生物治疗患者则没有明显改善。

在接受生物治疗的患者中,冠状动脉斑块总负荷减少了5%,主要由非钙化斑块减少以及纤维脂肪负荷和坏死负荷的显着减少所驱动。

未接受生物治疗的患者斑块负荷或纤维负荷无显着变化,但纤维脂肪负荷显着增加,坏死细胞无显着增加。

在调整传统血管危险因素后,研究发现非钙化斑块的显着减少与生物治疗有关。

在使用生物疗法治疗一年后,使用抗肿瘤坏死因子疗法的患者非钙化斑块负荷减少5%,使用抗IL12/23疗法的非钙化斑块负荷减少2%,使用抗IL-17疗法的非钙化斑块负荷减少12%。

“除了加强银屑病与加速性心脏病的关联之外,治疗体内炎症源(在本例中是皮肤)可能对降低心血管风险很重要。”Mehta博士说,“我们仍需要对其他疾病状态进行更广泛的研究,以了解全身炎症状态下冠状动脉斑块的自然史。”

原始出处:Youssef A Elnabawi,  Amit K Dey,  Aditya Goyal, et al. Coronary artery plaquecharacteristics and treatment with biologic therapy in severe psoriasis:results from a prospective observational study. Cardiovascular Research, 05February 2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938926, encodeId=17091938926be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 13 02:53:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944584, encodeId=fb94194458496, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 23 19:53:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706444, encodeId=ead61e064440b, content=<a href='/topic/show?id=846b694053d' target=_blank style='color:#2F92EE;'>#生物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69405, encryptionId=846b694053d, topicName=生物疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944d31252792, createdName=124984edm32暂无昵称, createdTime=Fri Dec 27 01:53:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361401, encodeId=901b361401ea, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Feb 24 09:35:59 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-04-13 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938926, encodeId=17091938926be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 13 02:53:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944584, encodeId=fb94194458496, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 23 19:53:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706444, encodeId=ead61e064440b, content=<a href='/topic/show?id=846b694053d' target=_blank style='color:#2F92EE;'>#生物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69405, encryptionId=846b694053d, topicName=生物疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944d31252792, createdName=124984edm32暂无昵称, createdTime=Fri Dec 27 01:53:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361401, encodeId=901b361401ea, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Feb 24 09:35:59 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938926, encodeId=17091938926be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 13 02:53:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944584, encodeId=fb94194458496, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 23 19:53:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706444, encodeId=ead61e064440b, content=<a href='/topic/show?id=846b694053d' target=_blank style='color:#2F92EE;'>#生物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69405, encryptionId=846b694053d, topicName=生物疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944d31252792, createdName=124984edm32暂无昵称, createdTime=Fri Dec 27 01:53:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361401, encodeId=901b361401ea, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Feb 24 09:35:59 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1938926, encodeId=17091938926be, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Apr 13 02:53:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944584, encodeId=fb94194458496, content=<a href='/topic/show?id=411de6300ad' target=_blank style='color:#2F92EE;'>#粥样硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76300, encryptionId=411de6300ad, topicName=粥样硬化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b30d401, createdName=huangshifeng, createdTime=Tue Jul 23 19:53:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706444, encodeId=ead61e064440b, content=<a href='/topic/show?id=846b694053d' target=_blank style='color:#2F92EE;'>#生物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69405, encryptionId=846b694053d, topicName=生物疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944d31252792, createdName=124984edm32暂无昵称, createdTime=Fri Dec 27 01:53:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361401, encodeId=901b361401ea, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Sun Feb 24 09:35:59 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-02-24 kafei

    学习了谢谢

    0

相关资讯

Wellcome:医药研发投资回报率高达25%

研究机构的发现为我们进行长期投资运作提供了安全保障,让我们更好地了解投资资金与健康利益之间的有效转化。

钱其军:十年内60%癌症患者花10多万元就可消褪肿瘤

【编者按】细胞免疫疗法利用病人自身的免疫细胞来清除肿瘤细胞,是目前抗癌领域最火爆的概念。作为热门疗法之一,数百个CAR-T(嵌合抗原受体T细胞免疫疗法)临床项目正在全球如火如荼地开展,截至今年7月底,中国有123项研究,仅次于美国的136项。11月8日,上海细胞治疗工程技术研究中心主任钱其军教授在2017国际精准医疗学术及产业论坛媒体见面会上表示,中国有望步入全球CAR-T领域第一梯队。随着国

Semin Arthritis Rheu:托珠单抗治疗巨细胞动脉炎的疗效

在临床实践中,TCZ可使难治性GCA快速而持续的改善。

2018 SER建议:生物疗法治疗中轴型脊柱关节炎

2018年10月,西班牙风湿病学会(SSR)发布了应用生物疗法治疗中轴型脊柱关节炎建议,本文为SER生物疗法治疗中轴型脊柱关节炎共识的第3次更新,作为指导建议主要目的是帮助风湿病学科医生在应用生物疗法治疗中轴型脊柱关节炎时提供指导。

BRIT J DERMATOL:研究确定生物疗法对牛皮癣的长久效果!

生物治疗牛皮癣在临床试验中取得了良好的效果,因为大多数的分析都集中在单一生物制剂的短期结果,人们对临床实践的长期结果一直知之甚少,因此不断切换生物制剂是常见的。近期,发表于《英国皮肤病》杂志上的文章中,报道了来自瑞典研究人员们长达10年的研究,此次试验参与者共计583人,试验显示了生物制剂的长期有效性。

Clin Gastroenterol Hepatol:孕期接受生物疗法是否影响宝宝出生后对疫苗的反应?

炎症性肠病(IBD)通常在育龄女性中发病,而使用免疫调节剂对于生育、妊娠、婴儿结局的影响是临床医生和患者共同关注的部分。2018年1月,发表在《Clin Gastroenterol Hepatol》的一项由美国科学家进行的研究,考察了IBD孕妇接受生物疗法是否影响婴儿对疫苗的应答。